{"id":7368,"date":"2020-01-21T16:54:36","date_gmt":"2020-01-21T11:24:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7368"},"modified":"2021-07-24T12:57:45","modified_gmt":"2021-07-24T07:27:45","slug":"imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102","title":{"rendered":"Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. <\/strong><\/h2>\n\n\n\n<p>Imfinzi, a\nmonoclonal antibody, binds and inhibits the interaction of PD-L1 with PD-1 and\nCD80. The drug blocks tumour\u2019s immune-evading mechanism and releases the\ninhibition of the immune response.<\/p>\n\n\n\n<p>Hepatocellular cell carcinoma is the most common type of primary cell carcinoma, with a prevalence of 105,785 in 2017, and is expected to rise in coming years. <\/p>\n\n\n\n<p>The recommendation came after the results from the Phase III trial HIMALAYA, which evaluated Imfinzi in combination with tremelimumab in patients suffering from unresectable, advanced HCC. The study is the first trial to test dual immune checkpoint blockade in the 1<sup>st<\/sup> line advanced HCC treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Novartis\nhas recently got approval from the EU for its secondary progressive multiple\nsclerosis (SPMS) drug, Mayzent. <\/strong><\/h2>\n\n\n\n<p>The\napproval of the EU will make Mayzent the first and only orally indicated\ntreatment for SPMS with active diseases demonstrated by relapses or imaging\nfeatures of inflammatory activity.<\/p>\n\n\n\n<p>The approval\ncame after the results of the drug obtained during the randomised,\ndouble-blind, placebo-controlled Phase III EXPAND clinical trial, which\nevaluated the safety and efficacy in 1,651 SPMS patients from 31 countries.<\/p>\n\n\n\n<p>Novartis gained approval from the USFDA in March last year for Mayzent for relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease, in adults. Moreover, the Australian Therapeutic Goods Administration (TGA) recommended its use from November onwards, and filings are in process in Switzerland, Japan, Canada and China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Verrica\nPharmaceuticals has announced the positive results of a study evaluating VP-102 <\/strong><strong>for\nthe treatment of molluscum contagiosum. <\/strong><\/h2>\n\n\n\n<p>Tested in the pivotal Phase 3 CAMP trials, VP-102 (cantharidin 0.7% topical solution), is the company\u2019s lead product. The results showed complete elimination of lesions in all body regions. <\/p>\n\n\n\n<p>The disease significantly affects the head, neck, abdomen, back, buttocks, and other body parts as well. <\/p>\n\n\n\n<p>If approved,\nVP-102 would form a better treatment option to even treat sensitive zones such\nas groin of the body. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. Imfinzi, a monoclonal antibody, binds and inhibits the interaction of PD-L1 with PD-1 and CD80. The drug blocks tumour\u2019s immune-evading mechanism and releases the inhibition of the immune response. Hepatocellular cell carcinoma is the most common [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7369,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,17970,17967,3053,423,583,17968,17969],"industry":[17225],"therapeutic_areas":[17227,17228],"class_list":["post-7368","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-hepatocellular-cell-carcinoma","tag-imfinzi","tag-mayzent","tag-novartis","tag-tremelimumab","tag-verrica-pharmaceuticals","tag-vp-102","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lates Pharma Happenings for Novartis; Verrica Pharma and AZ<\/title>\n<meta name=\"description\" content=\"The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lates Pharma Happenings for Novartis; Verrica Pharma and AZ\" \/>\n<meta property=\"og:description\" content=\"The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-21T11:24:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/21164906\/Pharma_news-21.01.2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lates Pharma Happenings for Novartis; Verrica Pharma and AZ","description":"The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102","og_locale":"en_US","og_type":"article","og_title":"Lates Pharma Happenings for Novartis; Verrica Pharma and AZ","og_description":"The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC.","og_url":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-01-21T11:24:36+00:00","article_modified_time":"2021-07-24T07:27:45+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/21164906\/Pharma_news-21.01.2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102","url":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102","name":"Lates Pharma Happenings for Novartis; Verrica Pharma and AZ","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/21164906\/Pharma_news-21.01.2020.jpg","datePublished":"2020-01-21T11:24:36+00:00","dateModified":"2021-07-24T07:27:45+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The US FDA has recently granted Orphan Drug Designation to AstraZeneca\u2019s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/imfinzi-combo-gets-odd-mayzent-gets-eu-nod-positive-results-of-vp-102#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/21164906\/Pharma_news-21.01.2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/21164906\/Pharma_news-21.01.2020.jpg","width":772,"height":482,"caption":"Pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/21164906\/Pharma_news-21.01.2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hepatocellular Cell Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Imfinzi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Mayzent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Tremelimumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Verrica Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">VP-102<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Hepatocellular Cell Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Imfinzi<\/span>","<span class=\"advgb-post-tax-term\">Mayzent<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Tremelimumab<\/span>","<span class=\"advgb-post-tax-term\">Verrica Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">VP-102<\/span>"]}},"comment_count":"1","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 21, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 21, 2020 4:54 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7368"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7369"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7368"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7368"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}